Utilizing catalytic Topo II inhibitor to target reestablished androgen receptor signaling in castration-resistant prostate cancer
Prostate cancer, the most common malignancy in Canadian men, is a leading cause of cancer-related male mortality. Androgen deprivation therapy is the first-line treatment for advanced prostate cancer. However, a fatal relapse to androgen deprivation therapy is inevitable, which is often characterize...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2017
|
| Online Access: | http://hdl.handle.net/2429/61243 |